New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
09:57 EDTMBII, IRM, DVA, TMST, RYAM, EVAR, IGXT, CA, SFXE, NTAP, KONA, ELGX, RESI, VAR, RCPTOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Altisource Residential (RESI) initiated with a Neutral at Citigroup... CA Technologies (CA) initiated with a Buy at Standpoint Research... DaVita (DVA) initiated with a Buy at Jefferies... Endologix (ELGX) initiated with an Outperform at Credit Suisse... IntelGenx (IGXT) initiated with a Buy at H.C. Wainwright... Iron Mountain (IRM) resumed with an Overweight at JPMorgan... Kona Grill (KONA) initiated with a Buy at KeyBanc... Lombard Medical (EVAR) initiated with an Outperform at Credit Suisse... Marrone Bio (MBII) initiated with an Outperform at RW Baird... NetApp (NTAP) initiated with a Buy at Standpoint Research... Rayonier Advanced Materials (RYAM) initiated with a Buy at DA Davidson... Receptos (RCPT) initiated with a Buy at Nomura... SFX Entertainment (SFXE) initiated with an Overweight at Albert Fried... TimkenSteel (TMST) initiated with a Buy at Jefferies... Varian Medical (VAR) initiated with a Neutral at ISI Group... Williams Partners (WPZ) initiated with a Buy at UBS.
News For RESI;CA;DVA;ELGX;IGXT;IRM;KONA;EVAR;MBII;NTAP;RYAM;RCPT;SFXE;TMST;VAR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
November 20, 2014
17:23 EDTRYAMRayonier Advanced Materials to replace Symmetry Medical in S&P 600 on 11/28
Subscribe for More Information
17:22 EDTRYAMCalifornia Resources Corp. to replace Rayonier Advanced in S&P 400 on 11/28
Subscribe for More Information
16:18 EDTCACA Technologies initiated with a Buy at Jefferies
Subscribe for More Information
08:45 EDTEVARLombard Medical's Aorfix stent graft shows positive results in two-year trial
Lombard Medical presented efficacy and safety data from the two-year follow up of the U.S. Pythagoras pre-marketing approval trial of Aorfix, the endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees. The data showed 100% freedom from aneurysm rupture, 98% freedom from Type I & III endoleaks and 99% freedom from device migration in patients with a 60 to 90 degree aortic neck angulation, a group typically considered difficult-to-treat and associated with poor treatment outcomes.
07:16 EDTIGXTSingular Research to hold a conference
Subscribe for More Information
07:13 EDTELGXCanaccord to hold a forum
Subscribe for More Information
November 19, 2014
06:06 EDTRCPTReceptos 3.6M share Secondary priced at $100.00
The deal size was increased to $360M from $325M. Credit Suisse and Leerink acted as joint book running managers for the offering.
November 18, 2014
12:42 EDTRCPTReceptos volatility at low end of range
Receptos overall option implied volatility of 53 compares to its 8-week average of 61 according to Track Data, suggesting decreasing price movement.
11:00 EDTELGXEndologix to host investor meeting
Subscribe for More Information
07:36 EDTCAUBS to hold a conference
Global Technology Conference to be held in Sausalito, California on November 18-20 with webcasted company presentations to begin on November 18 at 10:45 am; not all company presentations may be webcasted. Webcast Link
07:11 EDTELGXEndologix completes patient enrollment in Nellix EVAS FORWARD-IDE clinical trial
Endologix announced that it has completed patient enrollment in the EVAS FORWARD-IDE clinical trial, the company's U.S. pivotal clinical trial designed to evaluate the safety and effectiveness of the Nellix EndoVascular Aneurysm Sealing System for the endovascular repair of infrarenal abdominal aortic aneurysms, or AAA. Primary endpoint analysis results at one-year and beyond will be used to support the company's premarket approval, or PMA, application to the FDA for the Nellix EVAS System. The EVAS FORWARD-IDE clinical trial enrolled 179 patients at 29 centers in the U.S. and Europe. Enrollment under an extended investigation phase is anticipated to begin shortly and will continue during the pivotal trial follow-up period and PMA preparation/review process. Based on current assumptions and timelines, the company anticipates FDA approval of the Nellix System in the U.S. before the end of 2016.
November 17, 2014
16:02 EDTRCPTReceptos files to sell common stock, no amount given
Receptos intends to use the net proceeds received from this offering to fund continued development of its product candidate RPC1063 in ongoing and planned clinical trials for Relapsing Multiple Sclerosis, Ulcerative Colitis and Crohn's Disease, continued development of its in-licensed product candidate RPC4046 in an ongoing clinical trial for Eosinophilic Esophagitis, ongoing preclinical and research programs, and working capital and other general corporate purposes. Credit Suisse Securities and Leerink Partners LLC are acting as joint lead book-running managers for the offering. Evercore Group L.L.C. and BMO Capital Markets Corp. are acting as book-running managers. Wedbush PacGrow Life Sciences and Nomura Securities International, Inc. are acting as co-managers.
10:41 EDTRCPTReceptos 'priced beyond perfection,' may offer shares, TheStreetSweeper says
Subscribe for More Information
10:27 EDTRCPTReceptos mentioned cautiously by TheStreetSweeper
10:00 EDTSFXESFX Entertainment makes strong progress on growth, says Albert Fried
Subscribe for More Information
09:57 EDTCACA Technologies management to meet with JPMorgan
Subscribe for More Information
November 16, 2014
14:08 EDTDVADaVita announces collaboration with Medtronic
DaVita Kidney Care, a division of DaVita HealthCare Partners (DVA) and leading provider of kidney care services, announced a collaboration with Medtronic (MDT) to better understand cardiovascular health in end stage renal disease, ESRD patients. The collaboration will focus on developing a pilot program using Medtronic's Reveal LINQ Insertable Cardiac Monitoring system to identify cardiac arrhythmias in patients receiving dialysis. "Medtronic recently announced data at the American Society of Nephrology meeting that showed a higher incidence of arrhythmias in patients receiving hemodialysis," said Ven Manda, vice president, Renal Care Solutions at Medtronic. "We are pleased to pursue this collaboration with DaVita to monitor more patients and gather additional data that will further our understanding of the relationship between dialysis and cardiac events in ESRD patients." "Given the high incidence rate of cardiovascular disease and events in ESRD patients, we believe that by collaborating with Medtronic, we can gain knowledge to help improve the lives of ESRD patients," said Mahesh Krishnan, vice president for clinical innovation and public policy for DaVita HealthCare Partners. "Through the collaboration we expect to utilize innovative monitoring technology and data from our DaVita Kidney Care information systems across the country. This effort is poised to improve the lives of patients by proactively detecting and preventing cardiac complications."
November 14, 2014
09:38 EDTIRMJANA Partners gives quarterly update on stakes
NEW STAKES: AMD (AMD), AECOM Technology (ACM), Alibaba (BABA), McDonald's (MCD), Amgen (AMGN), Gaming and Leisure Properties (GLPI), Iron Mountain (IRM), iRobot (IRBT), Seadrill Partners (SDLP), Valeant (VRX). INCREASED STAKES: eBay (EBAY), Charter (CHTR), Groupon (GRPN), HD Supply (HDS), Hertz (HTZ). DECREASED STAKES: Apache (APA). LIQUIDATED STAKES: CBS (CBS), Endo (ENDP), FMC Corporation (FMC), SeaWorld (SEAS), SunEdison (SUNE).
07:09 EDTSFXESFX Entertainment reports Q3 EPS 0c, consensus 6c
Reports Q3 revenue $143.5M, consensus $165.26M. During the three months ended September 30, 2014, SFX produced and promoted a total of 267 events, which attracted over 1,559,000 attendees, including 27 festivals that each attracted over 10,000 attendees.
November 13, 2014
07:36 EDTNTAPNetApp price target raised to $47 from $45 at Brean Capital
Brean Capital raised its price target on NetApp to $47 from $45 following its Q2 results. The firm feels the company's balance sheet and free cash flow generation will underpin a capital return program. Brean Capital reiterates its Buy rating on NetApp shares.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use